The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study - Agnelli, G (J Clin Oncol, 2011)
(suppl; abstr LBA9014).